Saturday, October 7, 2017: 10:30 AM-12:00 PM
At the conclusion of this session, participants will be able to:
- discuss the current status of establishing an etiology and diagnostic testing for Kawasaki Disease.
- describe adjunctive and second/third line therapies that can be considered for Kawasaki Disease patients.
- review recommendations for follow up of Kawasaki Disease patients based on degree of coronary artery involvement.
Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Medical students and residents, Members-in-training, Pharmacists, Researchers
Trainee, Pediatric ID
Marsha Anderson, MD, FIDSA, University of Colorado SOM
Samuel Dominguez, MD, PhD, Childrens Hospital Colorado, University of Colorado SOM
Preeti Jaggi, MD, Nationwide Children's Hospital, The Ohio State University
Maximum of 1.50 hours of AMA PRA Category 1 Credit™
ACPE 1.5 knowledge-based contact hours of pharmacy CE